| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ELP3_0003500 | Intron-Exon-Intron | chr8:27984474-27995408 | chr8:28126957-28137891 | 120 nt | 0.2833 |
| hsa_ELP3_0003600 | Intron-Exon-Intron | chr8:27984474-28013549 | chr8:28126957-28156032 | 97 nt | 0.4536 |
| hsa_ELP3_0003700 | Intron-Exon-Intron | chr8:27984474-28019595 | chr8:28126957-28162078 | 88 nt | 0.4545 |
| hsa_ELP3_0003800 | Intron-Exon-Intron | chr8:27985564-28019595 | chr8:28128047-28162078 | 2405 nt | 0.4403 |
| hsa_ELP3_0003900 | Intron-Exon-Intron | chr8:27987006-27995408 | chr8:28129489-28137891 | 496 nt | 0.4778 |
| hsa_ELP3_0004000 | Intron-Exon-Intron | chr8:27987006-28019595 | chr8:28129489-28162078 | 82 nt | 0.4634 |
| hsa_ELP3_0004300 | Exon-Exon | chr8:27987019-27989921 | chr8:28129502-28132404 | 289 nt | 0.4637 |
| hsa_ELP3_0004400 | Exon-Exon | chr8:27987019-28016150 | chr8:28129502-28158633 | 640 nt | 0.4734 |
| hsa_ELP3_0004500 | Intron-Intron | chr8:27987922-27988393 | chr8:28130405-28130876 | 472 nt | 0.4364 |
| hsa_chr8_0287800 | Intergenic-Intergenic | chr8:27989880-27995263 | chr8:28132363-28137746 | 91 nt | 0.4615 |
A study in human bladder cancer demonstrated that the circELP3 contributes to cancer progression and cisplatin resistance [Huang et al. DOI:10.3390/cells11091381].